Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Stat Med ; 24(12): 1791-806, 2005 Jun 30.
Article in English | MEDLINE | ID: mdl-15806619

ABSTRACT

Traditional sample size calculations for randomized clinical trials depend on somewhat arbitrarily chosen factors, such as type I and II errors. Type I error, the probability of rejecting the null hypothesis of no difference when it is true, is most often set to 0.05, regardless of the cost of such an error. In addition, the traditional use of 0.2 for the type II error means that the money and effort spent on the trial will be wasted 20 per cent of the time, even when the true treatment difference is equal to the smallest clinically important one and, again, will not reflect the cost of making such an error. An effectiveness trial (otherwise known as a pragmatic trial or management trial) is essentially an effort to inform decision-making, i.e. should treatment be adopted over standard? As such, a decision theoretic approach will lead to an optimal sample size determination. Using incremental net benefit and the theory of the expected value of information, and taking a societal perspective, it is shown how to determine the sample size that maximizes the difference between the cost of doing the trial and the value of the information gained from the results. The methods are illustrated using examples from oncology and obstetrics.


Subject(s)
Clinical Trials as Topic/methods , Randomized Controlled Trials as Topic/statistics & numerical data , Bayes Theorem , Canada , Humans , Randomized Controlled Trials as Topic/methods , Research Design , Sample Size
2.
Stat Med ; 24(13): 1965-82, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-15803442

ABSTRACT

Clinical trials of cost-effectiveness are often conducted in more than one country. The two most common ways of dealing with the multinational nature of the data are either to calculate a pooled estimate or to stratify results by country. Since the between-country heterogeneity in costs is potentially substantial, pooled estimates may be difficult to interpret for any one country. Policy decisions are often made at a national level, and so country-specific results are important. However, country-specific analyses will be based on fewer patients and will often fail to provide adequate precision for statistical analyses. Shrinkage estimation is a compromise between these two methods and has been used successfully in other fields. These estimates are country-specific yet less variable than those derived through a subgroup approach. Univariate and multivariate shrinkage estimators for costs and effects are proposed, then compared with one another and to the traditional methods in a simulation study. The methods are illustrated using data from a multinational trial evaluating the cost-effectiveness of three thrombolytic drug regimens in patients with acute myocardial infarction.


Subject(s)
Clinical Trials as Topic/economics , Cost-Benefit Analysis/statistics & numerical data , Internationality , Myocardial Infarction/drug therapy , Humans , Ontario , Thrombolytic Therapy
3.
Health Econ ; 14(4): 327-38, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15685652

ABSTRACT

The growing number of multinational clinical trials in which patient-level health care resource data are collected have raised the issue of which is the best approach for making inference for individual countries with respect to the between-treatment difference in mean cost. We describe and discuss the relative merits of three approaches. The first uses the random effects pooled estimate from all countries to estimate the difference for any particular country. The second approach estimates the difference using only the data from the specific country in question. Using empirical Bayes estimation a third approach estimates the country-specific difference using a variance-weighted linear sum of the estimates provided by the other two approaches. The approaches are illustrated and compared using the data from the ASSENT-3 trial.


Subject(s)
Health Care Costs/statistics & numerical data , International Cooperation , Randomized Controlled Trials as Topic/economics , Randomized Controlled Trials as Topic/statistics & numerical data , Abciximab , Antibodies, Monoclonal/economics , Antibodies, Monoclonal/therapeutic use , Anticoagulants/economics , Anticoagulants/therapeutic use , Bayes Theorem , Enoxaparin/economics , Enoxaparin/therapeutic use , Heparin/economics , Heparin/therapeutic use , Humans , Immunoglobulin Fab Fragments/economics , Immunoglobulin Fab Fragments/therapeutic use , Multicenter Studies as Topic , Myocardial Infarction/drug therapy , Myocardial Infarction/economics
4.
Eur Child Adolesc Psychiatry ; 13(3): 159-65, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15254843

ABSTRACT

We report a prospective longitudinal study of cognitive development in a series of 20 clinic-referred infants with Tuberous Sclerosis. The infants were seen between the ages of 11 and 37 months and were assessed regularly at 6-month periods using a within-subjects repeated measures design. Assessment using the Mullen Scales of Early Learning, a measure of cognitive and motor showed that with the exception of one child, all children had composite developmental quotients that fell into the mentally retarded range of intellectual functioning. In general, the infants' developmental quotients changed little between 12 and 36 months of age. Developmental progress was evident; however, with small incremental changes in raw scores for subjects over the course of the study. In three children, the developmental quotient changed by more than 20 points during the course of the study. The findings are considered in relation to the neurobiological risk factors for cognitive development in Tuberous Sclerosis.


Subject(s)
Child Development , Cognition Disorders/etiology , Tuberous Sclerosis/complications , Tuberous Sclerosis/psychology , Child, Preschool , Epilepsy , Female , Humans , Infant , Intellectual Disability , Male , Motor Skills , Prospective Studies , Risk Factors
5.
Dis Colon Rectum ; 47(7): 1119-26, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15164254

ABSTRACT

PURPOSE: Although ulcerative colitis commonly affects young females, the impact of ulcerative colitis and its treatment on female fertility have not been well studied. The purpose of this survey was to examine the impact of ulcerative colitis and ileal pouch-anal anastomosis on female reproductive ability. METHODS: Demographic, reproductive history, and disease history information were obtained via a questionnaire mailed to females who had pelvic pouch surgery or nonoperative management for ulcerative colitis. Based on age at diagnosis, age at surgery, and marital status, 153 females who had pelvic pouch surgery and 60 females who had nonoperative management for ulcerative colitis were identified for inclusion. Patients were asked if they attempted to become pregnant, when relative to their diagnosis or surgery, and if they were successful. Married or cohabiting females aged 18 to 44 years who failed to become pregnant during 12 months of unprotected intercourse were defined as infertile. RESULTS: The infertility rate was significantly higher in females who had pelvic pouch surgery compared with females managed nonoperatively (59/153 (38.1 percent) vs. 8/60 (13.3 percent), respectively; P < 0.001). There was no difference in female fertility after diagnosis with ulcerative colitis compared with before diagnosis (odds ratio, 0.68; P = 0.23). In contrast, there was a 98 percent reduction in fertility after pelvic pouch surgery compared with before surgery (odds ratio, 0.021; P < 0.0001). By logistic regression, increasing age was the only factor associated with failure to become pregnant after surgery (odds ratio, 1.136 per additional year of age; P = 0.027). CONCLUSIONS: Females with ulcerative colitis who are managed nonoperatively have normal fertility, which suggests that ulcerative colitis and medical therapy do not decrease female reproductive ability. After pelvic pouch surgery for ulcerative colitis, female fertility is significantly decreased and this problem should be discussed routinely with patients considering this procedure.


Subject(s)
Colitis, Ulcerative/surgery , Infertility, Female/etiology , Pregnancy Complications , Proctocolectomy, Restorative/adverse effects , Adolescent , Adult , Cohort Studies , Colitis, Ulcerative/therapy , Female , Humans , Infertility, Female/therapy , Pregnancy , Reproductive Techniques , Surveys and Questionnaires
6.
Exp Gerontol ; 39(4): 615-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15050297

ABSTRACT

BACKGROUND: Previous studies have reported on the association between white blood cell counts, in particular monocytes, and cardiovascular disease, but have predominantly been conducted on middle-aged men. We examined whether this association is sustained in an elderly population-based sample. METHODS: Two samples of individuals aged 65 years and older living in Cambridge and Nottingham were recruited from the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Venepuncture was undertaken in 1046 individuals, excluding only those who had probable dementia or were physically frail. Monocyte, neutrophil, lymphocyte, eosinophil and basophil counts were analysed for possible associations with history of cardiovascular disease. RESULTS: We found that monocyte and neutrophil counts were both significantly associated with history of cardiovascular disease, with respective odds ratios of 1.48 (95% CI 1.22-1.79) and of 1.44 (95% CI 1.19-1.75) per count tertile. These relationships remained significant on adjusting for age, sex, smoking and body mass index. We found no evidence of association between lymphocyte, eosinophil or basophil counts and history of cardiovascular disease. CONCLUSIONS: Monocyte and neutrophil counts are both associated with cardiovascular disease in a relatively healthy elderly population.


Subject(s)
Cardiovascular Diseases/blood , Monocytes/pathology , Neutrophils/pathology , Aged , Female , Humans , Leukocyte Count , Male , Odds Ratio , Risk Factors , Smoking/blood
7.
Mech Ageing Dev ; 124(4): 449-51, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12714252

ABSTRACT

Comparisons of lymphocyte subsets show that the ratio of CD4 to CD8 is usually greater than one. Inversion of this ratio was found to predict survival in a Swedish octogenarian sample (n=27 deaths), although individual lymphocyte subsets did not predict survival. We have examined these relationships in a larger sample (n=153 deaths). Inversion of the CD4 to CD8 ratio was present in 16% of the sample and predicted survival when adjusted for age but not when adjusted for sex. For individual lymphocyte subsets, higher CD4 and CD19 percentages were associated with better survival, but only the CD19 percentage remained significant when adjusted for age and sex.


Subject(s)
Aging/immunology , CD4-CD8 Ratio , Lymphocyte Subsets , Aged , Aged, 80 and over , Cluster Analysis , Female , Humans , Male , Mortality , Predictive Value of Tests , Survival Rate
8.
Blood ; 99(12): 4547-53, 2002 Jun 15.
Article in English | MEDLINE | ID: mdl-12036887

ABSTRACT

Deletions of the derivative chromosome 9 have recently been reported in chronic myeloid leukemia. These deletions are large, occur at the time of the Philadelphia (Ph) translocation, span the translocation breakpoint, and represent a powerful prognostic indicator. However, the molecular mechanisms responsible for the poor prognosis associated with deletions are obscure, and several possible models are investigated here. First, we demonstrate that all derivative chromosome 9 deletions detected by fluorescence in situ hybridization were associated with an absence of ABL-BCR expression. However, loss of ABL-BCR expression also occurred without an overt deletion, suggesting the existence of other mechanisms by which ABL-BCR transcription can be abolished. Furthermore, analysis of survival in 160 patients demonstrated that loss of ABL-BCR expression, in contrast to deletion status, was not an indicator of poor prognosis. Second, we addressed the possibility that concomitant small deletions of the Ph chromosome modulate BCR-ABL transcription. Real-time reverse-transcription polymerase chain reaction was used to demonstrate that derivative chromosome 9 deletions were not accompanied by altered levels of BCR-ABL transcripts. Third, deletions may represent a consequence of genetic instability within the target cell at the time of the Ph translocation, with the poor prognosis reflecting a predisposition to subsequent additional genetic alterations. However, patients with deletions do not exhibit an increased frequency of secondary cytogenetic changes following disease progression. Taken together, these data support a model in which deletions of the derivative chromosome 9 result in rapid disease progression as a result of the loss of one or more genes within the deleted region.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 9 , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Adult , Blast Crisis/genetics , Disease Progression , Female , Fusion Proteins, bcr-abl/genetics , Fusion Proteins, bcr-abl/metabolism , Humans , Karyotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Male , Middle Aged , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Philadelphia Chromosome , Prognosis , RNA, Messenger/analysis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...